Q-omics provides the consensus-scored ILF2P1 profile across patient tissues and cancer cell-line models. ILF2P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, ILF2P1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ILF2P1 RNA expression shows 16,452 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight PAAD, KIRC, and CCRCC as cancer lineages where ILF2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ILF2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ILF2P1 survival associations across molecular data types. ILF2P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ILF2P1 RNA expression–survival associations across cancer types. High ILF2P1 expression shows unfavorable associations in PAAD, ACC, MESO, DLBC and LIHC, but favorable associations in CESC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify PAAD as the clearest survival context for ILF2P1 RNA expression.
This table summarizes ILF2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ILF2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ILF2P1 shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in COAD, UCEC and STAD. The KIRC box plot shows higher ILF2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.040, t-test p < 0.001).
This table shows molecular features associated with ILF2P1 in patient tissues and cancer cell lines. In patient samples, ILF2P1 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
